Syndax upbeat on PhII data in breast cancer; Two misfit genes point to new way to treat asthma;

@FierceBiotech: Big Pharma VCs may complement traditional venture. Story | Follow @FierceBiotech

@JohnCFierce: Crescendo bioscience (diagnostics) gets $56M in venture cash, myriad debt deal tied to buyout option. Item | Follow @JohnCFierce 

@RyanMFierce: Bruce Booth analyzes our shrinking biotech eco system, 27% drop in biopharmas over past 5 years. News | Follow @RyanMFierce

> Researchers in Australia have found two mutant genes linked with asthma, and one of them could be targeted with Roche's rheumatoid arthritis drug tocilizumab. Report

> TONIX Pharmaceuticals has highlighted upbeat Phase IIa data on the use of low doses of cyclobenzaprine to treat the core symptoms of fibromyalgia. The firm is developing TNX-102, a reformulated version of the drug. TONIX release

> BIO backed the U.S. Senate's passage of the patent reforms in the Leahy-Smith America Invents Act as important to protecting the intellectual property of biotech firms. Item

> Syndax reported positive results from a Phase II trial of its lead drug entinostat against breast cancer. Article

Pharma News

@FiercePharma: Genzyme apologizes for latest Fabrazyme delay. News | Follow @FiercePharma 

> Dendreon cuts 500 jobs in Provenge retrenchment. News

And Finally... Weight Watchers' program trumped doctors' orders by a wide margin in a recent study of weight-loss interventions. Report

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.